Tyra Biosciences Inc TYRA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TYRA is a good fit for your portfolio.
News
-
Tyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights
-
Tyra Biosciences to Present at Upcoming Investor Conferences
-
Tyra Biosciences to Present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference
-
Tyra Biosciences, Inc. Announces $200 Million Private Placement Financing
-
Tyra Biosciences Gets Rare Pediatric Disease Designation For Achondroplasia Therapy
-
Tyra Biosciences Receives FDA Rare Pediatric Disease Designation for TYRA-300 for the Treatment of Achondroplasia
-
Tyra Biosciences Gets FDA Orphan Designation for TYRA-300 in Achondroplasia
Trading Information
- Previous Close Price
- $15.11
- Day Range
- $15.09–15.47
- 52-Week Range
- $10.38–20.67
- Bid/Ask
- $15.26 / $15.65
- Market Cap
- $812.54 Mil
- Volume/Avg
- 17,916 / 133,301
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company’s in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 38
- Website
- https://www.tyra.bio
Comparables
Valuation
Metric
|
TYRA
|
CLDX
|
CGEM
|
---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 3.18 | 4.82 | 1.79 |
Price/Sales | — | 260.58 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
TYRA
CLDX
CGEM
Financial Strength
Metric
|
TYRA
|
CLDX
|
CGEM
|
---|---|---|---|
Quick Ratio | 13.27 | 13.69 | 16.60 |
Current Ratio | 13.80 | 13.87 | 17.07 |
Interest Coverage | — | — | — |
Quick Ratio
TYRA
CLDX
CGEM
Profitability
Metric
|
TYRA
|
CLDX
|
CGEM
|
---|---|---|---|
Return on Assets (Normalized) | −22.50% | −30.49% | −24.60% |
Return on Equity (Normalized) | −23.73% | −33.19% | −25.95% |
Return on Invested Capital (Normalized) | −27.79% | −32.85% | −29.67% |
Return on Assets
TYRA
CLDX
CGEM
Biotechnology Industry Comparables
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Qssqxdwk | Jtfz | $554.7 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Kvfqmtsn | Mdsdmnb | $103.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Xzmdqck | Zgyrf | $97.8 Bil | |
MRNA
| Moderna Inc | Wtxpglcn | Pxxh | $38.8 Bil | |
ARGX
| argenx SE ADR | Jrsxbmc | Ctff | $22.0 Bil | |
BNTX
| BioNTech SE ADR | Grxcscmd | Jxgvf | $21.2 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Btlttysvd | Kskwsp | $18.2 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Nbsnpcck | Vmlvs | $17.3 Bil | |
RPRX
| Royalty Pharma PLC Class A | Qcvgfwdhvv | Xvwwd | $12.5 Bil | |
INCY
| Incyte Corp | Jrltrghl | Pvgfl | $11.5 Bil |